References
- Sandborn WJ, Gasink C, Gao L-L, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;3:1519–1528.
- Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
- Kopylov U, Afif W, Cohn A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease-the McGill experience. J Crohns Colitis. 2014;8:1516–1522.
- Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti–tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242–250.
- Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232–1243.
- Greenup AJ, Rosenfeld G. Development of amyotrophic lateral sclerosis during ustekinumab use for refractory Crohn’s disease. Ann Clin Case Rep. 2017;2:1281.
- Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
- Khorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662–1669.
- Harris KA, Horst S, Gadani A, et al. Patients with refractory Crohn’s disease successfully treated with ustekinumab. Inflamm Bowel Dis. 2016;22:397–401.
- Sandborn W, Rutgeerts P, Gasink C, et al. Op010 Long term efficacy and safety of ustekinumab for Crohn’s disease: results from IM-UNITI long-term extension through 2 years. J Crohns Colitis. 2017;11:S6.
- Danese S, Bonovas S, Peyrin-Biroulet L. Positioning ustekinumab in Crohn’s disease: from clinical evidence to clinical practice. J Crohns Colitis. 2017 [2017 Jun 2]. DOI:10.1093/ecco-jcc/jjx079
- Moćko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of Crohn’s disease: a systematic review and network meta-analysis. Pharmacol Rep. 2016;68:1237–1243.
- Data on file. Reports of pregnancy with ustekinumab: STE/Inj/DoF/Sep2010/EMEA001. Beerse, Belgium: Janssen; 2010.
- Venturin C, Nancey S, Danion P, et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol. 2017;17:80.
- Galli-Novak E, Mook SC, Büning J, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e191–e192.
- Cortes X, Borrás-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther. 2017;42:234–236.
- Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007;133:1106–1112.